USA flag logo/image

An Official Website of the United States Government

Field-Practical Automated Battery for Assessing and Monitoring Cognitive

Award Information

Agency:
Department of Defense
Branch:
Office of the Secretary of Defense
Award ID:
54729
Program Year/Program:
2001 / SBIR
Agency Tracking Number:
O012-0332
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
OMNISITE BIODIAGNOSTICS, INC.
101 West Sixth Street Suite 200 Austin, TX 78701
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2001
Title: Field-Practical Automated Battery for Assessing and Monitoring Cognitive
Agency / Branch: DOD / OSD
Contract: N00014-02-M-0060
Award Amount: $99,997.00
 

Abstract:

OmniSite BioDiagnostics Inc. (OmniSite) proposes to aid in the field diagnosis of soft tissue injuries of DOD troops by development of DNA aptamer-based assays for protein markers and hydroxylated amino acids in diluted whole blood. DNA aptamers arenovel, inexpensive replacement reagents for antibodies that do not require animal hosts for production and are therefore inexpensive and simple to produce. In phase I, OmniSite will focus its assay development efforts on skeletal Troponin I (sTnI),creatine kinase isoform MM1 (CK-MM1), carbonic anhydrase III (CA III), hydroxylysine and hydroxyproline. This panel of candidate markers for soft tissue injury will be simultaneously analyzed in OmniSite's partitioned microfluidic cartridge byfluorescence polarization (FP). FP provides rapid, highly sensitive and accurate one-step binding assays without the need for wash steps. OmniSite has an intellectual property position, which allows miniaturization of FP into an inexpensive handheldreader format. The fusion of these powerful technologies will provide the DOD with facile and reliable field assays for soft tissue injuries. In Phase II, OmniSite will sequence the DNA aptamers, refine the FP-aptamer assays and deliver an FP readerprototype with model assays for testing. If successful, OmniSite will have an assay system that numerous point-of-care facilities may desire to aid in diagnosis of soft tissue injuries or cardiac infarctions for the general public.

Principal Investigator:

John Bruno
Chief Technical Officer
5124797732
bruno@spec.com

Business Contact:

Donald Gorsuch
President
5124797732
gorsuch@spec.com
Small Business Information at Submission:

OMNISITE BIODIAGNOSTICS, INC.
101 West Sixth Street, Suite 200 Austin, TX 78701

EIN/Tax ID: 742975605
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No